S U P R A C H E M
Think OUTSIDE The Bond
TM
SUPRAMOLECULAR ENGINEERING
Time To TRANSFORM CHEMISTRY in the Life Sciences
QAI Output: (Right) AGE Crosslink Breaker Adaptive Compound (Includes Van Der Waal's Radius Overlays);
(Background) Valsartin Solvated; (Left) Serotonin; (Below) Buckyball, Chelation Overlay and Insulin
QAI Output:
Decorated Buckyball
QAI Output: Chelation Overlay
SUPRAMOLECULAR ENGINEERING
.
PRECISION DRUG DESIGN
BASED ON SUPRAMOLECULAR
RECOGNITION OF BIOMARKERS
.
Think OUTSIDE The Bond
INDEFINITE SCALABILITY
PRECISION DRUG DESIGN
Uniquely, SUPRACHEM performs supramolecular chemistry, in silico. We apply QAI to precisely design molecules optimized for inter-molecular, non-bonded interactions in chemical systems, such as biological drug targets. Molecular recognition rests upon the molecular information stored in the interacting chemical species. This molecular information encodes the properties of self-organization within unique chemical environments, such as between a drug and its biological target. This makes the precision design of compounds that respond adaptively to specific chemical environments possible in biological systems.
Adaptive compounds dynamically adjust their activity based upon the chemical environment. The QAI Reactor MatrixTM optimizes the adaptive molecular recognition properties in compound design to achieve a critical balance between target recognition and drug-like properties. Drug-like properties are often the cause of poor drug performance in clinical evaluation. The essential features and chemical correspondences of drug-like properties are the accumulation of years of medicinal chemistry experience and wisdom, but in the end are empirically rule-based. QAI attempts to achieve this balance through first principles, using its quantum molecular analysis engine. Optimizing this balance can translate into better drug-like properties, improving ADME behavior and potentially enhancing safety, i.e. the “therapeutic window."
Time To TRANSFORM CHEMISTRY
SUPRACHEM designs molecules for pharmaceutical and biotechnology companies to develop and take to market as drugs. Central to our approach to significantly expedite early stage pre-clinical drug discovery is our application of QAI REACTOR MATRIX(TM).
QAI is a supramolecular chemistry in silico platform. It is the first and only of its kind. With advanced machine learning artificial intelligence -- and precision at femtometer resolution\femtojoule energy -- QAI enables the precise design and optimization of molecular systems at the subatomic level of detail. Molecular systems of any size, from a single particle to a large complex molecular system containing trillions of particles, such as protein/protein interactions, can be modeled, analyzed, modified and engineered rapidly for selecting optimized structures for synthesis or bioengineering.
Of great interest to pharmaceutical and biotechnology companies is our capability to precisely design new molecular entities (NME's), i.e. drug or biologic candidates. A major strategy for pharmas and biotechs to improve productivity is to partner with small innovators like SUPRACHEM, for contract research and/or to in-license molecules at various stages of pre-clinical development. We are a very efficient partner in this regard.
Aside from the significant time and cost reduction during drug discovery, we aim to greatly minimize risk by delivering more than one drug candidate. Our precision-based, risk averse approach is coupled with the potential for our pharma and biotech customers and partners to gain a time to market advantage, which can ultimately yield several hundreds of millions to billions of dollars in revenue for a SUPRACHEM-designed drug candidate.
TM
“During our [year and a half] relationship, they [Suprachem] have developed new algorithms and tools that allow for direct visualization of the sub-atomic
interactions that makes their tools so unique. The use of these visualizations have allowed us to have meaningful conversations about the results and
to see the important features and relationships between the molecules. These specific visualizations are unique [to Suprachem],
and provide a view of the intermolecular interactions that is not available with other tools.” -- DUPONT
ALL MOLECULAR IMAGES ON THIS WEBSITE
C SUPRACHEM
QAI Output: Insulin
Click Image to View PDB Reference
of ASYMMETRIC UNIT
